KR20160119867A - 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료 - Google Patents

항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료 Download PDF

Info

Publication number
KR20160119867A
KR20160119867A KR1020167027017A KR20167027017A KR20160119867A KR 20160119867 A KR20160119867 A KR 20160119867A KR 1020167027017 A KR1020167027017 A KR 1020167027017A KR 20167027017 A KR20167027017 A KR 20167027017A KR 20160119867 A KR20160119867 A KR 20160119867A
Authority
KR
South Korea
Prior art keywords
antibody
antigen
binding portion
ctla
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167027017A
Other languages
English (en)
Korean (ko)
Inventor
마리아 쥬리-쿤켈
폴 개그니어
데이빗 펠트퀘이트
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Priority to KR1020227030567A priority Critical patent/KR20220127940A/ko
Publication of KR20160119867A publication Critical patent/KR20160119867A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167027017A 2014-03-05 2015-03-04 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료 Ceased KR20160119867A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227030567A KR20220127940A (ko) 2014-03-05 2015-03-04 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461948428P 2014-03-05 2014-03-05
US61/948,428 2014-03-05
US201461977318P 2014-04-09 2014-04-09
US61/977,318 2014-04-09
US201461992729P 2014-05-13 2014-05-13
US61/992,729 2014-05-13
US201462005600P 2014-05-30 2014-05-30
US62/005,600 2014-05-30
PCT/US2015/018727 WO2015134605A1 (en) 2014-03-05 2015-03-04 Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227030567A Division KR20220127940A (ko) 2014-03-05 2015-03-04 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료

Publications (1)

Publication Number Publication Date
KR20160119867A true KR20160119867A (ko) 2016-10-14

Family

ID=52686508

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167027017A Ceased KR20160119867A (ko) 2014-03-05 2015-03-04 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
KR1020227030567A Ceased KR20220127940A (ko) 2014-03-05 2015-03-04 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
KR1020247031210A Pending KR20240144452A (ko) 2014-03-05 2015-03-04 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020227030567A Ceased KR20220127940A (ko) 2014-03-05 2015-03-04 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
KR1020247031210A Pending KR20240144452A (ko) 2014-03-05 2015-03-04 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료

Country Status (6)

Country Link
US (4) US20170088626A1 (OSRAM)
EP (2) EP3572430A3 (OSRAM)
JP (4) JP2017507155A (OSRAM)
KR (3) KR20160119867A (OSRAM)
CN (2) CN106255510A (OSRAM)
WO (1) WO2015134605A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019151712A1 (ko) * 2018-02-05 2019-08-08 한국과학기술원 암 환자에서 면역 치료 효과를 예측하는 방법

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY160203A (en) 2009-03-30 2017-02-28 Eisai R&D Man Co Ltd Liposome composition
CA2873402C (en) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US20160303231A1 (en) * 2013-12-11 2016-10-20 Robert Iannone Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
SG11201604738TA (en) 2013-12-12 2016-07-28 Shanghai Hengrui Pharm Co Ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN118286440A (zh) 2014-02-04 2024-07-05 辉瑞大药厂 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
BR112017004826A2 (pt) 2014-09-13 2017-12-12 Novartis Ag terapias de combinação de inibidores de alk
CN107206088A (zh) * 2014-12-05 2017-09-26 豪夫迈·罗氏有限公司 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物
BR112017018234A2 (pt) 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
EP3265122B1 (en) * 2015-03-04 2022-05-04 Merck Sharp & Dohme Corp. Combination of pembrolizumab and eribulin for treating triple-negative breast cancer
EP3067062A1 (en) * 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
HUE050750T2 (hu) 2015-05-29 2021-01-28 Agenus Inc CTLA-4 elleni antitestek és eljárások alkalmazásukra
KR102712880B1 (ko) 2015-06-16 2024-10-02 메르크 파텐트 게엠베하 Pd-l1 길항제 조합 치료
JP7014706B2 (ja) 2015-07-13 2022-02-01 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法
UA124379C2 (uk) 2015-08-11 2021-09-08 Усі Байолоджікс Айрленд Лімітед Нові антитіла проти білка pd-1
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
WO2017049199A1 (en) 2015-09-16 2017-03-23 Board Of Regents, University Of Texas System Combination of topoisomerase-i inhibitors with immunotherapy in the treatment of cancer
BR112018006817A2 (pt) * 2015-10-08 2018-10-23 Macrogenics Inc método de tratamento do câncer
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
US11209441B2 (en) 2016-04-05 2021-12-28 Bristol-Myers Squibb Company Cytokine profiling analysis
EP3440112A4 (en) 2016-04-08 2019-10-09 X4 Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
JP7015237B2 (ja) 2016-04-28 2022-02-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
MX2019003755A (es) 2016-10-06 2019-08-12 Pfizer Regimen de dosificacion de avelumab para el tratamiento de cancer.
TWI764943B (zh) * 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
EP4234691A3 (en) 2016-10-14 2023-10-18 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
EA201991383A1 (ru) 2016-12-07 2019-12-30 Эйдженус Инк. Антитела против ctla-4 и способы их применения
KR102603681B1 (ko) 2016-12-07 2023-11-17 아게누스 인코포레이티드 항체 및 이의 사용방법
US11407830B2 (en) 2017-01-09 2022-08-09 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
CN106729705B (zh) * 2017-01-23 2018-04-06 河南省华隆生物技术有限公司 一种药物组合物及其应用
MY194278A (en) 2017-02-15 2022-11-25 Taiho Pharmaceutical Co Ltd Pharmaceutical composition
EP3366703B1 (en) * 2017-02-28 2019-04-03 Ralf Kleef Immune checkpoint therapy with hyperthermia
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3682882A4 (en) * 2017-09-08 2021-06-02 Taiho Pharmaceutical Co., Ltd. ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
JP7098748B2 (ja) 2017-12-20 2022-07-11 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
EP3842070A4 (en) * 2018-07-18 2022-04-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. DRUG COMBINATION OF QUINOLINE DERIVATIVE AND ANTIBODY
CN110734493B (zh) * 2018-07-20 2021-12-17 厦门大学 抗pd-1抗体及其用途
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CN113196061A (zh) 2018-10-18 2021-07-30 豪夫迈·罗氏有限公司 肉瘤样肾癌的诊断和治疗方法
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020097106A1 (en) * 2018-11-05 2020-05-14 Aveo Pharmaceuticals, Inc. Use of tivozanib to treat subjects with refractory cancer
CN118267468A (zh) 2019-01-25 2024-07-02 正大天晴药业集团股份有限公司 治疗肿瘤的联用药物组合物
US12318403B2 (en) 2019-03-07 2025-06-03 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
WO2021088853A1 (zh) * 2019-11-04 2021-05-14 正大天晴药业集团股份有限公司 喹啉衍生物与pd-1单抗的药物组合
EP4069729B1 (en) 2019-12-06 2025-01-22 Precision BioSciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
CN115605493A (zh) 2020-03-20 2023-01-13 吉利德科学公司（Us） 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
US20240269142A1 (en) 2021-05-13 2024-08-15 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
EP4351564A1 (en) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
CA3222595A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN119654148A (zh) * 2022-05-09 2025-03-18 癌症研究所(D/B/A福克斯切斯癌症中心研究所) 用于治疗癌症的Curaxin与免疫检查点抑制剂的组合
KR20240068809A (ko) 2022-10-31 2024-05-20 재단법인 아산사회복지재단 Ifitm3 억제제를 포함하는 신장암 예방 또는 치료용 약학적 조성물
EP4637821A1 (en) * 2022-12-23 2025-10-29 Actinium Pharmaceuticals, Inc. Her3 radioimmunotherapy for the treatment of solid cancers
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
CN120501749A (zh) * 2025-05-28 2025-08-19 皖南医学院 Prmt5抑制剂或其与抗pd-1抗体联合在制备治疗肾癌的药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
AU2007272330A1 (en) * 2006-07-13 2008-01-17 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
CN104013956B (zh) * 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
JP5945096B2 (ja) * 2008-07-04 2016-07-05 小野薬品工業株式会社 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
MX360254B (es) 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP2734551B1 (en) 2011-07-24 2018-01-10 Cure Tech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
CA2873402C (en) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CN103242448B (zh) * 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
CN103536917B (zh) * 2013-10-30 2015-03-11 苏州丁孚靶点生物技术有限公司 干扰素在治疗肿瘤中的用途及相关的产品和方法
CN118286440A (zh) * 2014-02-04 2024-07-05 辉瑞大药厂 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019151712A1 (ko) * 2018-02-05 2019-08-08 한국과학기술원 암 환자에서 면역 치료 효과를 예측하는 방법

Also Published As

Publication number Publication date
US20220389110A1 (en) 2022-12-08
EP3572430A3 (en) 2020-02-12
JP2020007331A (ja) 2020-01-16
CN114432440A (zh) 2022-05-06
US20250297028A1 (en) 2025-09-25
KR20220127940A (ko) 2022-09-20
JP2024178325A (ja) 2024-12-24
US20190263923A1 (en) 2019-08-29
JP2022058698A (ja) 2022-04-12
JP2017507155A (ja) 2017-03-16
CN106255510A (zh) 2016-12-21
EP3114144A1 (en) 2017-01-11
WO2015134605A1 (en) 2015-09-11
EP3572430A2 (en) 2019-11-27
US20170088626A1 (en) 2017-03-30
KR20240144452A (ko) 2024-10-02

Similar Documents

Publication Publication Date Title
US20250297028A1 (en) Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
JP7356531B2 (ja) 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用
KR102870759B1 (ko) 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
JP6840127B2 (ja) がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用
AU2013263076B2 (en) Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
KR102515509B1 (ko) 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
CN106573977B (zh) 针对ceacam1的人源化抗体
US20180179282A1 (en) Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
US20170355768A1 (en) Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
JP2024012300A (ja) 医薬併用
US20230322928A1 (en) Treatment methods using ctla-4 and pd-1 bispecific antibodies
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
WO2022255248A1 (ja) 抗ｃｄ２６抗体と免疫チェックポイント阻害剤との併用療法
HK1251173A1 (en) Agent for enhancing immunity to cancer by using allergin-1 antagonist

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160929

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200304

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210729

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220214

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210729

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220214

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210929

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20220602

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220516

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220214

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210929

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210729

X601 Decision of rejection after re-examination
A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220902

PJ0201 Trial against decision of rejection

Patent event date: 20220902

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20220602

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20220214

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2022101001613

Request date: 20220902

J301 Trial decision

Free format text: TRIAL NUMBER: 2022101001613; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20220902

Effective date: 20230621

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20230621

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20220902

Decision date: 20230621

Appeal identifier: 2022101001613